Lusutrombopag Patent Expiration
Lusutrombopag is Used for managing thrombocytopenia in adult patients with chronic liver disease undergoing a procedure. It was first introduced by Vancocin Italia Srl
Lusutrombopag Patents
Given below is the list of patents protecting Lusutrombopag, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mulpleta | US9427402 | Preparation for improving solubility of poorly soluble drug | Sep 29, 2031 | Vancocin Italia |
| Mulpleta | US8530668 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | Jan 21, 2030 | Vancocin Italia |
| Mulpleta | US8889722 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | Jul 29, 2028 | Vancocin Italia |
| Mulpleta | US7601746 | Compounds exhibiting thrombopoietin receptor agonism |
Sep 05, 2024
(Expired) | Vancocin Italia |
Lusutrombopag's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List